A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs KD 025 (Primary) ; Itraconazole; Rabeprazole; Rifampicin
- Indications Autoimmune disorders; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Kadmon Corporation
- 12 Aug 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Number of treatment arms has been increased hence number of patients has also increased. Endpoints has also added.
- 11 Oct 2018 Planned number of patients changed from 40 to 78.